India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports
BUZZ-India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports Updates
** Nifty Pharma Index .NIPHARM down 1.52%
** Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS, Cipla CIPL.NS, Lupin LUPN.NS, Glenmark GLEN.NS, Dr Reddy's REDY.NS and Zydus ZYDU.NS decline 1.2%-3.9%, with Lupin the worst hit
** Trump says imported generic drugs will remain tariff-free for two years from August 1, before tariffs increase to 100% for one year and 200% thereafter
** "The headline is negative, but key details around implementation, legal challenges, exemptions and final scope remain unclear ... We would view it more as a policy signal than a quantifiable earnings event" - Niharika Agarwal, analyst at Nirmal Bang
** PL Capital says existing U.S. facilities may partly cushion impact, but two years is too short to relocate entire generic pharma value chain
** Motilal Oswal says tariff implementation remains uncertain, with major impact due from August 2028, near end of Trump's term
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses